COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer: COM33 sensitizes ovarian cancer to carboplatin

Despite favorable responses to platinum-based chemotherapy in ovarian cancer (OC), chemoresistance is still a major cause of treatment failure. Hence, we develop a novel synthetic agent, COM33, to relieve the chemoresistance caused by carboplatin. The anti-cancerous effects of the combination of COM...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhiyang, Jin, Li, Shen, Jian, Shi, Weihui, Xu, Yue, Ye, Longyun, Liu, Junxi, Pan, Jiexue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157527/
https://www.ncbi.nlm.nih.gov/pubmed/36647720
http://dx.doi.org/10.3724/abbs.2022195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157527/
https://www.ncbi.nlm.nih.gov/pubmed/36647720
http://dx.doi.org/10.3724/abbs.2022195

Ejemplares similares